喀什如何诊治滴虫性阴道炎喀什月经为什么一直不干净,喀什有哪些看男科,喀什包皮手术什么年龄做比较合适,喀什看男科疾病哪里好,喀什为什么男人会硬不起来,喀什检查包皮包茎 费用,喀什做包茎价格是多少

BEIJING, Jan. 31 (Xinhua) -- China's Ministry of Finance (MOF) said Monday it had allocated 28.23 billion yuan (4.27 billion U.S. dollars) to assure retired enterprise employees receive their pensions before the arrival of the Spring Festival.The State Council, or the Cabinet, decided at an executive meeting last December to raise the retired enterprise employees' pension about 10 percent from 2010 levels, or about 140 yuan per person per month in 2011.The MOF also said local governments had issued 10.24 billion yuan of festival subsidies to 85.97 million people.The Spring Festival, the Chinese lunar New Year is a time for family reunions in China. It falls on Feb. 3 this year.

SAN FRANCISCO, April 7 (Xinhua) -- A latest research has shown that worldwide camera phone sales, driven by fast growing high- tier camera phone market, will top 1 billion units for the first time in 2011.According to the study by Strategy Analytics, a global independent research and consulting firm, sales of camera phones are projected to grow by 21 percent from 918 million units last year to 1.114 billion units in 2011, which will be the first time that annual volumes of camera phones have exceeded the 1-billion mark."The fastest growing segment of the camera phone market will be the high-tier. We forecast camera phones with sensors of eight megapixels and above to grow a healthy 240 percent worldwide during 2011," Neil Mawston, director at Strategy Analytics, said in a statement on Thursday.He added that smartphone vendors, such as Nokia and HTC, are increasingly loading their flagship models with more megapixels to deliver improved imaging quality for premium operator services.Statistics from Strategy Analytics show that some 4.2 billion camera phones have been sold worldwide since 2000.

WINDHOEK, May 21 (Xinhua) -- Top Chinese legislator Wu Bangguo on Saturday met with Namibian President Hifikepunye Pohamba on advancing the bilateral cooperation to further develop the partnership with Namibia.Wu, chairman of the National People's Congress (NPC) Standing Committee, China's top legislative body, extended Chinese President Hu Jintao's greetings to Pohamba and hailed an "all- weather" partnership forged between the two nations.Namibia is one of the youngest states in Africa, which became fully independent in 1990.Wu reviewed the profound friendship between the two countries, which established diplomatic ties one day after Namibia's announcement of its full independence.Wu said the two countries have reaped good harvests in cooperation in the fields of politics, trade, culture, education, public health and culture in recent years, which has already set a model for countries engaged in the South-South cooperation.He also highlighted the mutual understanding and support on issues concerning each other's core interests, and to bring the bilateral economic and trade cooperation to a new high, Wu put forward a three-point proposal concerning the importation of the husbandry and aquatic products, resource and mining as well as the infrastructure construction.Namibia is a nation with significant influence in the southern Africa, Wu said, vowing that China will work with the Namibian side to push the bilateral partnership to a higher level.For his part, Pohamba welcomed Wu's visit, the first one ever paid by a Chinese top legislator, and spoke highly of China's long-standing support for Namibia's national liberation and construction.Namibia will develop the long-term and strategic cooperation in a much broader domain with China and welcomes more Chinese businesses to invest in the country, the Namibian president said.On the China-Afrcia relationship, the two leaders stressed that the two sides should work closer under the framework of the Forum of China-Africa Cooperation to boost political mutual trust, substantial and pragmatic cooperation on trade and humanitarian exchanges, especially those among the young generations, so as to further enrich a new China-Africa partnership.Namibia is the first leg of Wu's 12-day African-Asian tour. He will also visit Angola, South Africa and Maldives.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

WASHINGTON, April 13 (Xinhua) -- The U.S. Food and Drug Administration (FDA) announced on Wednesday that it has approved the cPAX Aneurysm Treatment System for surgery on brain aneurysms that are difficult to manage because of their size and shape.An aneurysm is a bulge in the wall of a blood vessel, which can rupture as it increases in size, causing hemorrhage or death. Brain aneurysms often produce no symptoms until they grow and press on nerves in the brain, or until they begin to leak blood or rupture.Aneurysms can be repaired in two ways: surgeons can close the base of the aneurysm with a surgical clip, or use a technique commonly known as coiling, in which surgeons use a catheter to thread metallic coils through a blood vessel in the groin and into the blood vessel in the brain that contains the aneurysm. Surgeons then fill the aneurysm with the detachable coils, which block it from circulation and cause blood to clot, effectively destroying the aneurysm.Aneurysms larger than 10 millimeters are difficult to treat with clipping or coiling. The cPAX device system is indicated for use in those brain aneurysms."Like coiling, the cPAX Aneurysm Treatment System is a form of endovascular repair," said Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health. "But instead of tiny metallic coils, it uses a special polymer material to fill the space within the aneurysm."According to the FDA, the cPAX device system is indicated for use in adults aged 22 and older and should not be used in patients with an active infection or in those in whom anticoagulation and antiplatelet therapy is contraindicated.